Suchergebnisse - "Hasselbalch, Hans Carl"

PubPharm (7)

1

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

enthalten in: Expert review of hematology | 2017

von Bjørn, M. | Hasselbalch, H.

2

Optimal therapy for polycythemia vera and essential thrombocythemia : Preferred use of interferon therapy based on phase 2 trials

enthalten in: Hematology (Amsterdam, Netherlands) | 2016

von Silver, R. | Hasselbalch, H.

3

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

enthalten in: Leukemia research | 2013

von Stauffer Larsen, T. | Iversen, K. | Hansen, E. | +12

4

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

enthalten in: Expert review of hematology | 2013

von Silver, R. | Kiladjian, J. | Hasselbalch, H.

5

Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α

enthalten in: Blood | 2011

von Riley, C. | Jensen, M. | Brimnes, M. | +4

6

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

enthalten in: Hematology (Amsterdam, Netherlands) | 2009

von Larsen, T. | Møller, M. | de Stricker, K. | +6

7

Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin

enthalten in: American journal of hematology | 2002

von Hasselbalch, H. | Clausen, N. | Jensen, B.

1
[1]